The ten million wired the next morning.
It bought us time.
Not safety.
Time.
Then Dr. Edwin Schiff called.
He had been Sarah’s palliative care doctor at Sterling Weston, the kind man with tired eyes who stopped talking about miracles when my daughter needed comfort.
“I saw your ex-husband on television,” he said. “Using her name. It isn’t right.”
I held the phone tighter.
“What isn’t right?”
“The Celestea extension trial. Sarah should not have been pushed into it at that stage. The toxicity risk was severe. There were other comfort-focused options. I argued against enrollment.”
“Who overruled you?”
“The trial committee. Dr. Thorne initially. But pressure came from higher. Hospital administration. Board level.”
Board level.
Grayson was chairman.
Dr. Schiff’s voice dropped.
“I saw the raw data. Not the published data. The real adverse-event rates at Sterling Weston were catastrophic. Organ failure. Neurological events. Metabolic collapse. They explained them away as disease progression.”
My hand went cold around the phone.
“Do you have proof?”
“No. Access is audited. But the data exists. And there is a pathology report from Sarah’s case that should have triggered a formal safety review. It disappeared.”
The line went quiet.
Then he said, barely above a whisper, “Your daughter was not the only one.”
That night, I returned to the Fifth Avenue penthouse under the pretext of collecting Sarah’s childhood things.
Grayson agreed because he wanted me gone from his life cleanly, and because arrogance makes men stupid in familiar rooms.
The penthouse looked like a hotel that had forgotten anyone ever lived there. Sarah’s shoes were gone from the foyer. Her finger paintings were gone from the refrigerator. Her bedroom had been turned into a guest room with beige linen and a scent of disinfectant.
I found what I came for in the closet: a shoebox labeled
S’s First Shoes
.
Beneath tiny sandals was her secret diary, a unicorn composition notebook.
The real mission was Grayson’s office.
I used the key he forgot I still had.
Inside, I plugged a wireless transmitter disguised as a phone charger into the outlet behind his desk. Sam waited downstairs in a van, ready to pull data from his network. I slipped a keylogger between his desktop tower and the wall.
As I turned to leave, I saw a framed photo on the shelf.
Grayson.
The CEO of NovaLife.
All smiling at a charity golf tournament.
The inscription read:
To Grayson—a true partner in healing. Onward.
Healing.
The word felt obscene.
The elevator pinged as I reached the foyer.
Grayson stepped inside, early.
He stopped.
His eyes narrowed.
“Philippa.”
“I was leaving.”
“What’s in the box?”
“Our daughter’s childhood,” I said. “Or what’s left of it.”
He stared, suspicious.
Then his gaze hardened.
“Stay away from Catherine. The customs nonsense, the gallery whispers, your little art performance—it ends.”
I said nothing.
He stepped closer.
“You got your money. You got your freedom. Grieve. Paint. Move to Texas. But stay away from my business.”
Then he smiled coldly.
“And tell your father the ten million he just loaned you won’t be enough to keep your little short alive.”
He knew.
Not everything.
But enough.
I let him see nothing.
“I’m just a grieving mother, Grayson,” I said. “What business could I possibly have with you?”
I walked past him.
Downstairs in Sam’s van, the files began downloading.
By midnight, Lena was staring at the first batch with a face gone pale.
Emails.
Spreadsheets.
Internal messages.
A note from NovaLife’s CFO sent three days before the FDA announcement:
Breakthrough designation imminent. Contact confirms. Time press release for maximum market impact. Begin planned selloff at open plus thirty. Muse buy-side support ready to stabilize above $85.
Grayson’s reply:
Proceed. Refined Sterling Weston package must remain locked. Thorne compliant. K. will close the acquisition before month end.
There it was.
Insider trading.
Market manipulation.
Data fraud.
Then the final file.
A scanned pathology report.
Sarah Sterling.
The report noted an unprecedented toxic metabolic response consistent with trial-drug interaction.
Red stamp:
NOT FOR INCLUSION IN MASTER TRIAL FILE. CHAIRMAN’S EYES ONLY.
Chairman.
He had seen proof.
He had buried it.
I opened Sarah’s diary with shaking hands.
The last entry was written in uneven pencil from her hospital bed.
Mommy’s eyes are sad. Daddy says the medicine is magic. The magic hurts. I told Doctor Thorne it hurts. He said be brave for Daddy. I’m trying. I drew a bird. I want to fly away from the hurt. Will magic ever not hurt?
The room disappeared.
I pressed the notebook to my chest and bent over it like my body might fold around the words and protect them retroactively.
It was too late to protect her.
Not too late to answer.
I created one encrypted evidence packet.
Recipients: SEC Enforcement, FBI Financial Crimes, FBI Art Crime, the New York Times investigative desk, and Athena Capital’s ten largest investors.
Scheduled send time: Tuesday, 2:15 p.m.
Fifteen minutes after the Federal Reserve interest-rate announcement.
Lena looked at me.
“If the Fed hikes only twenty-five basis points, we may still lose everything.”
“And if they hike fifty?”
“Grayson’s leverage detonates.”
I hit schedule.
The packet locked.
The countdown began.
“Then we wait for the floor to fall.”
Tuesday, 2:00 p.m.
The Nemesis war room smelled of cold coffee, overheated electronics, and fear.
Lena and I sat before six screens. One showed the Federal Reserve chairman stepping toward a podium in Washington. Another showed NovaLife’s stock still glowing green. Another displayed our portfolio dashboard in a red so deep it looked arterial.
Our short was underwater.
My mother’s trust was on the line.
My future was on the line.
But beneath all that, colder and steadier, was Sarah’s diary on the table beside me.
Will magic ever not hurt?
The Fed chairman spoke in slow, bloodless sentences.
Maximum employment.
Price stability.